Biocatalysis, using enzymes for organic synthesis, has emerged as powerful tool for the
synthesis of active pharmaceutical ingredients (APIs). The first industrial biocatalytic …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

Importance Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet
therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited …

Background Current guidelines recommend potent platelet inhibition with prasugrel or
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …

Normal platelet function is critical to blood hemostasis and maintenance of a closed
circulatory system. Heightened platelet reactivity, however, is associated with …

Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the
prevention of atherothrombotic events in patients with acute coronary syndromes and for …

In physiological hemostasis a prompt recruitment of platelets on the vessel damage prevents
the bleeding by the rapid formation of a platelet plug. Qualitative and/or quantitative platelet …

Background Elderly patients are at high risk of ischaemic and bleeding events. Platelet
function monitoring offers the possibility to individualise antiplatelet therapy to improve the …

Background: The incidence, predictors, and prognostic impact of post-discharge bleeding
(PDB) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) …

Aims Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis
(ST) and bleeding, standardized and clinically validated thresholds for accurate risk …